Charles River Laboratories International, Inc. Stock price

Equities

CRL

US1598641074

Biotechnology & Medical Research

Market Closed - Nyse 04:00:02 2024-03-18 pm EDT 5-day change 1st Jan Change
262.1 USD +1.22% Intraday chart for Charles River Laboratories International, Inc. -0.36% +10.88%
Sales 2024 * 4.22B Sales 2025 * 4.53B Capitalization 13.46B
Net income 2024 * 420M Net income 2025 * 525M EV / Sales 2024 * 3.66 x
Net Debt 2024 * 1.98B Net Debt 2025 * 1.51B EV / Sales 2025 * 3.3 x
P/E ratio 2024 *
32.3 x
P/E ratio 2025 *
26.3 x
Employees 21,100
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.21%
More Fundamentals * Assessed data
Dynamic Chart
Argus Raises Price Target on Charles River Laboratories International to $290 From $200, Maintains Buy Rating MT
Charles River Laboratories International, Navega Therapeutics Partner for Production of AAV-Based Gene Therapy MT
Charles River Laboratories International, Inc. and Navega Therapeutics Announce Comprehensive Gene Therapy Manufacturing Collaboration CI
Transcript : Charles River Laboratories International, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 10:15 AM
Charles River Laboratories International Insider Sold Shares Worth $959,545, According to a Recent SEC Filing MT
DURECT Corporation and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for Alzet® Product Line in U.S. and Canada CI
Charles River Laboratories International Insider Sold Shares Worth $1,268,500, According to a Recent SEC Filing MT
Charles River Laboratories International, Wheeler Bio Collaborate on Portable CMC Platform MT
Transcript : Charles River Laboratories International, Inc. - Special Call
Charles River Laboratories International Sets Accord With Wheeler Bio on Clinical Trials MT
Charles River Laboratories International, Inc. Announces Strategic Agreement with Wheeler Bio, Inc CI
Deutsche Bank Raises Charles River Laboratories International Price Target to $275 From $245, Maintains Buy Rating MT
Morgan Stanley Raises Price Target on Charles River Laboratories International to $235 From $205, Keeps Equalweight Rating MT
TD Cowen Adjusts Charles River Laboratories International's PT to $260 From $193, Keeps Market Perform Rating MT
Stephens Adjusts Charles River Laboratories International's PT to $280 From $270, Keeps Overweight Rating MT
More news
1 day+1.22%
1 week-0.36%
Current month+3.12%
1 month+7.01%
3 months+14.92%
6 months+24.49%
Current year+10.88%
More quotes
1 week
255.04
Extreme 255.04
267.20
1 month
235.28
Extreme 235.28
275.00
Current year
201.01
Extreme 201.01
275.00
1 year
161.65
Extreme 161.65
275.00
3 years
161.65
Extreme 161.65
460.21
5 years
95.58
Extreme 95.58
460.21
10 years
49.60
Extreme 49.6
460.21
More quotes
Managers TitleAgeSince
Chief Executive Officer 73 75-12-31
Director of Finance/CFO 51 22-04-24
Chief Operating Officer 54 89-03-31
Members of the board TitleAgeSince
Director/Board Member 78 07-12-02
Director/Board Member 76 02-12-31
Director/Board Member 68 19-09-30
More insiders
Date Price Change Volume
24-03-18 262.1 +1.22% 379,817
24-03-15 259 -0.59% 835,185
24-03-14 260.5 -0.26% 404,573
24-03-13 261.2 -1.11% 577,573
24-03-12 264.1 +0.39% 503,373

Delayed Quote Nyse, March 18, 2024 at 04:00 pm EDT

More quotes
Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows: - discovery and safety assessment services (61.5%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides; - development of solutions used in drug manufacturing processes (19.9%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies; - development and sale of research models and related services (18.6%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies. Net sales break down by source of income between sales of services (80.9%) and sales of products (19.1%). Net sales are distributed geographically as follows: the United States (58.9%), Europe (26%), Canada (10%), Asia/Pacific (4.8%) and other (0.3%).
Related indices
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
262.1 USD
Average target price
260.3 USD
Spread / Average Target
-0.68%
Consensus
  1. Stock
  2. Equities
  3. Stock Charles River Laboratories International, Inc. - Nyse